Belantamab mafodotin is an anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
- Mechanism
- Curator reviewed · 6 references
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF). Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody dependant cell mediated cytoxicity.
BCMA is uniquely expressed on CD138-positive myeloma cells. Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells. Belantamab mafodotin binds to BCMA, is internalised into cells, and releases MMAF.
The MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis.
- Primary indication
- In the US, Belantamab mafodotin is indicated in combination with bortezomib and [dexamethasonethe] for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 2 prior therapies including a proteasome...Curator reviewed · 7 structured indications
- First approval
- Canada, 2025 · United States, 2020
- Also known as
- Belantamab Mafodotin-blmf
- Code names
- GSK-2857916 · J6M0-mcMMAF · WHO 10754
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Belantamab mafodotin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account